Abstract 50P
Background
Papillary thyroid carcinoma (PTC) has a specific integrin expression signature that correlates with histopathology, specific driver gene mutations, and aggressiveness of the disease. α3β1 integrin is overexpressed, it is involved in PTC cell motility and invasion and is associated with an advanced disease and a worst outcome. Histopathology studies indicate that fibronectin 1 (FN1) and its integrin ligand αVβ3 are overexpressed in PTC. In normal thyroid cells, fibronectin (FN) stimulates DNA synthesis, proliferation and survival through αVβ3 binding.
Methods
The mRNA expression of integrins and FN1 genes in normal thyroid tissues and PTC were assessed in the TCGA database. -The level of FN and αVβ3 in was assessed by immunofluorescence in PTC cell lines (BCPAP, K1) and in a normal thyroid cell line (Nthy-ori3-1). -The release and deposition of FN were estimated by enzyme-linked immunoassay. - The proliferation was measured by MTT assay. -The silencing of gene FN1 in the K1 cell line was performed with KN2.0, non-homology mediated CRISPR knockout kit (ORIGENE®).
Results
Analysis of the TCGA database on 402 PTC and 82 healthy tissues demonstrates that FN1 mRNA is 60 times more expressed in PTC than in healthy tissue and that the ITGAV and ITGB1 subunits are more expressed. The increase in FN1 and ITGAV mRNA expression is associated with metastatic lymph nodes, more advanced staging, extrathyroidal extension, and higher risk. PTC cells show higher expression of integrin αVβ3, the main receptor of FN1 and at the same time a high production of fibronectin. The gene FN1 was silenced in K1 cell line (K1FN1-/-). Both K1 and K1FN1-/- seeded in collagen coated plates attached and survived in the absence of serum. While K1 proliferated under these culture conditions, proliferation was almost absent in K1FN1-/- and was rescued by soluble FN.
Conclusions
Papillary thyroid carcinoma cells express high amounts of αVβ3 integrin and produce more fibronectin. - Fibronectin/ αVβ3 interaction could be a mechanism of disease progression in PTC. - Fibronectin can be a powerful prognostic indicator and a site of pharmacological intervention.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
University of Salerno.
Funding
Department of Medicine, Surgery and Dentistry, University of Salerno.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
72P - SNCG promotes the malignant progression of hepatocellular carcinoma by activation EGFR signaling and recycling
Presenter: Yue Chen
Session: Cocktail & Poster Display session
Resources:
Abstract
73P - TROP2 amplification is highly present in dedifferentiated liposarcoma: Data from the Cancer Genome Atlas (TCGA) in soft tissue sarcoma
Presenter: Sarah Orlando
Session: Cocktail & Poster Display session
Resources:
Abstract
74P - The influence of genetic phenotype on prognosis of osteosarcoma
Presenter: Nasirov Kamalovich
Session: Cocktail & Poster Display session
Resources:
Abstract
76P - Immune engager compounds screening using CRC patient-derived organoids
Presenter: Claudia Maria A. Pinna
Session: Cocktail & Poster Display session
Resources:
Abstract
77P - Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer
Presenter: Juan Jiménez-Vacas
Session: Cocktail & Poster Display session
Resources:
Abstract
78P - Exploring ecDNA heterogeneity and evolution in non-small cell lung cancer
Presenter: Jeanette Kittel
Session: Cocktail & Poster Display session
Resources:
Abstract
79P - Targeting galectin-9 in BRCA mutant breast cancer
Presenter: Chun Yan So
Session: Cocktail & Poster Display session
Resources:
Abstract
80P - Suppression of glioblastoma progression by FDA-approved central nervous system-accumulating drugs via autophagy modulation and ER stress-induced apoptosis
Presenter: Smita Dey
Session: Cocktail & Poster Display session
Resources:
Abstract
81P - Evaluating the effect of lenvatinib-resistance in hepatocellular carcinoma cells and in lenvatinib-resistant patient-derived PBMCs
Presenter: Luisa Amato
Session: Cocktail & Poster Display session
Resources:
Abstract
82P - Applying computational approaches to build a predictive protein structure and discover novel inhibitors for mitotic serine/threonine kinase BUB1B
Presenter: Joan Glenny Pescov
Session: Cocktail & Poster Display session
Resources:
Abstract